Key Takeaways DefenCath is CRMD's main growth driver, launched across inpatient and outpatient settings in 2024.DefenCath's sales in Q3 are expected to have been driven by strong uptake in the U.S. market.Melinta's $300M acquisition brings seven drugs, expanding CRMD's hospital and infection care portfolio.CorMedix’s (CRMD) DefenCath (Taurolidine + Heparin) is its lead marketed product and the primary revenue driver for the company. The FDA approved DefenCath in late 2023 as the first and only antimicrobial ...